CONTESSA/NEOCON-F trial: Assessing the effectiveness and safety of neoadjuvant chemotherapy followed by fertility-sparing surgery in FIGO 2018 stage IB2 cervical cancer

The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial

Sentinel node biopsy diminishes de use of adjuvant therapy in women with early cervical cancer in the SUCCOR cohort

Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a PARP inhibitor: detailed safety results from the Phase IIIb OReO/ENGOT-ov38 trial

Real-world safety, baseline characteristics and first-year therapy management in patients with BRCA1/BRCA2-mutated advanced ovarian cancer treated with olaparib tablets in the first-line maintenance setting: first analysis of the pan-European OVAL-1 study

Nutritional supplementation with myo-inositol-D-chiro-inositol: effect on reproductive system functionality in Long-term Survivors of Lymphoma

Overall Survival Results From ARIEL3: A Phase 3 Randomised, Double-blind Study of Rucaparib Vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma

The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775

The importance of pathological ultrastaging for sentinel lymph node biopsy in cervical cancer, the final outcome of the Sentix study (CEEGOG-CX01; ENGOT-CX2; NCT02494063).

Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer

Pelvic sentinel lymph node distribution; the final outcome of the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063).

Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: results from the randomized SCORPION Trial

Efficacy and safety of VB10.16, a therapeutic DNA vaccine specifically targeting antigen-cell presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis

Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study

Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab